Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Morphic Holding (MORF – Research Report) and Vertex Pharmaceuticals (VRTX – Research Report).
Morphic Holding (MORF)
RBC Capital analyst Gregory Renza maintained a Buy rating on Morphic Holding on February 22 and set a price target of $76.00. The company’s shares closed last Monday at $35.65.
According to TipRanks.com, Renza is a 5-star analyst with an average return of
Currently, the analyst consensus on Morphic Holding is a Strong Buy with an average price target of $61.50, implying a 74.5% upside from current levels. In a report issued on February 22, TD Cowen also maintained a Buy rating on the stock.
See today’s best-performing stocks on TipRanks >>
Vertex Pharmaceuticals (VRTX)
In a report issued on February 22, Brian Abrahams from RBC Capital maintained a Hold rating on Vertex Pharmaceuticals, with a price target of $417.00. The company’s shares closed last Monday at $433.48, close to its 52-week high of $448.40.
According to TipRanks.com, Abrahams is a 5-star analyst with an average return of
Vertex Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $438.13.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on MORF:
